<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83739">
  <stage>Registered</stage>
  <submitdate>20/03/2009</submitdate>
  <approvaldate>15/05/2009</approvaldate>
  <actrnumber>ACTRN12609000274279</actrnumber>
  <trial_identification>
    <studytitle>N-acetyl cysteine: could it be an effective adjuvant therapy in infertile women undergoing intra-cytoplasmic sperm injection (ICSI) in achieving more pregnancy?</studytitle>
    <scientifictitle>In women undergoing intra-cytoplasmic sperm injection (ICSI) using gonadotropin releasing hormone agonist (GnRHa) long protocol, does addition of N-acetyl cysteine (NAC) in comparison to the standard protocol achieves more pregnancy?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Infertility</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Triptorelin 0.1 mg subcutaneous injection daily from the midluteal phase of the pretreatment cycle followed directly by 1200 mg NAC orally daily in three divided doses (400mg each) starting from the first day of gonadotropin administration till the day of human chorionic gonadotrophin (hCG)</interventions>
    <comparator>Triptorelin 0.1 mg subcutaneous injection  daily from the midluteal phase of the pretreatment cycle till achieving endometrium &lt; 5 mm, no ovarian cysts, and serum estradiol &lt; 50 pg / ml, then the dose of triptorelin was reduced to 0.05 mg/day and ovarian stimulation was initiated with recombinant follicle stimulating hormone (rFSH) and human menopausal gonadotrophin (hMG). The dose was changed from day 6 of stimulation according to sequential transvaginal ultrasonography and serum estradiol. When at least three follicles had reached = 17 mm in diameter, human chorionic gonadotrophin (hCG), 10.000 IU was administered as a single intramuscular (IM) dose</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical pregnancy rate diagnosed by measuring serum human chorionic gonadotropin hormone and ultrasound scan</outcome>
      <timepoint>3 weeks after a (+)ve serum hCG</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Granulosa cell apoptosis using Annexin V-Propidium iodide Detection Flow Cytometry</outcome>
      <timepoint>within 1 hour of follicular aspiration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fertilization rate by inspecting the number of oocytes with 2 pronuclei and 2 polar bodies under dissecting microscope</outcome>
      <timepoint>16-18 hours after ICSI</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Grade I embryo (equal blastomeres without fragmentation under the microscope)</outcome>
      <timepoint>At the time of embryo transfer (ET)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ongoing pregnancy rate through ultrasound scan</outcome>
      <timepoint>12 weeks after a (+)ve serum hCG test</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women undergoing ICSI cycles for male infertility</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>37</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age &gt; 37 years, body mass index &lt; 18 or &gt; 29 kg/m2, cycles &lt; 24 days or &gt; 35 days, single ovary, day 3 follicle stimulating hormone 9.5 milli international unit/ml or more, basal total antral follicle count 6 or less, cases refused to sign a consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/09/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>76</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Eman, A. Elgindy</primarysponsorname>
    <primarysponsoraddress>Obstetrics &amp; Gynecology department, Faculty of Medicine, Zagazig University, Zagazig city, Ash Sharqiyah, 44519</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Eman, A. Elgindy</fundingname>
      <fundingaddress>Obstetrics &amp; Gynecology department, Faculty of Medicine, Zagazig University, Zagazig city, Ash Sharqiyah, 44519</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Ahmed M. El-Huseiny</sponsorname>
      <sponsoraddress>Obstetrics &amp; Gynecology department, Faculty of Medicine, Zagazig University, Zagazig city, Ash Sharqiyah, 44519</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Magdy I. Mostafa</sponsorname>
      <sponsoraddress>Obstetrics &amp; Gynecology department, Faculty of Medicine, Cairo University, El Manial, Cairo, 11451</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Ahmed M. Gaballah</sponsorname>
      <sponsoraddress>Clinical Pathology department, Faculty of Medicine, Zagazig University, Zagazig city, Ash Sharqiyah, 44519</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Taha A. Ahmed</sponsorname>
      <sponsoraddress>Obstetrics &amp; Gynecology department, Faculty of Medicine, Zagazig University, Zagazig city, Ash Sharqiyah, 44519</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The trial aims at testing the value of adding N-acetyl cysteine (as a powerful anti-oxidant) in achieving more pregnancies for infertile females undergoing intra-cytoplasmic sperm injection (ICSI) procedure using gonadotrophin releasing hormone agonist plus gonadotrophin ovarian stimulation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eman, A. Elgindy</name>
      <address>Obstetrics &amp; Gynecology department, Faculty of Medicine, Zagazig University, Zagazig city, Ash Sharqiyah, 44519</address>
      <phone>+20 1274 91143</phone>
      <fax />
      <email>eman_elgindy@hotmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Magdy I. Mostafa</name>
      <address>Obstetrics &amp; Gynecology department, Faculty of Medicine, Cairo University, El Manial, Cairo, 11451</address>
      <phone>+20 1052 07305</phone>
      <fax />
      <email>imagdy@link.net</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>